SINGAPORE (July 4): CIMB Research is maintaining its "add" recommendation on Best World with a higher target price of $1.61 from its previous $1.12 price target.

(See: Best World kept at ‘add’ by CIMB on strong 1Q showing)

This comes after the skincare manufacturer and distributor announced last Thursday that its subsidiary, Best World (ZheJiang) Pharmaceutical Co. (BWZ), has been granted a direct selling license by China’s Ministry of Commerce.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook